So big but so what? Innovent’s license deal fails to excite investors
The Chinese biotech is selling some cancer drug rights to a Japanese pharma giant for up to $11.4 billion, pocketing a big downpayment, so why did its stock price fall?…
FAST NEWS: Zai Lab’s Loss Widens as R&D Costs Surge
The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) on Thursday reported a $161 million net loss in the third quarter, 67% wider than its $96.41 million loss a year…
3D Medicines Bleeds Red Ink As It Struggles to Swim in ‘Red Ocean’
The loss-making innovative oncology drug company with just one approved product on the market is making a third tilt for a listing on the Hong Kong Stock Exchange Key Takeaways:…
RELATED ARTICLES
-
Big deal, bigger doubts: CSPC slides after $18.5 billion pact
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
-
RemeGen scores out-licensing triple play with AbbVie deal
9995.HK688331.SHG
- Jacobio Pharma poised to turn a profit from precision cancer drugs
-
CIG’s strong profit forecast fails to excite, hinting at fading AI euphoria
6166.HK603038.SHG
